KDR and neoplasm: VEGFR2 is a member of the tyrosine kinase receptor family, and its inhibition prevents angiogenesis by blocking phosphorylation and dimerization.2,3 VEGFR2 is crucial for normal physiological conditions, but its deregulation is associated with cancer.4 Tumour cells produce VEGF, which activates VEGFR2 and stimulates the growth of new blood vessels, encouraging tumour angiogenesis and cancer spread.5,6 Inhibiting VEGFR2 has emerged as a potential strategy to halt cancer growth, and various VEGFR2 inhibitors have undergone clinical testing, with some approved for use.